Popularity of Medical Cannabis and CBD Products Projected to Widen

NEW YORK, June 1, 2017 /PRNewswire/ --

Cannabidiol (CBD) is the part of the cannabis plant that is usually used for medical reasons. Growth of the medical cannabis market is expected to accelerate as the products become more popular treatments for various medical applications. Chronic pain, post-traumatic stress disorder (PTSD), sleep disorders, anxiety, nerve pain and others. A research report published by The Hemp Business Journal, estimated that the CBD market will grow to a $2.1 billion market in consumer sales by 2020 with $450 million of those sales coming from hemp-based sources. Those projected sales by 2020 show a 700% increase from 2016. In 2015, the market for consumer sales of hemp-derived CBD products was $90 million according to the report, plus another $112 million in cannabis-derived CBD products which were sold through dispensaries. This brings a total CBD market to $202 million as of last year. ChineseInvestors.com, Inc. (OTC: CIIX), CV Sciences, Inc. (OTC: CVSI), Cannabis Sativa, Inc. (OTC: CBDS), Medical Marijuana, Inc. (OTC: MJNA), Mentor Capital, Inc. (OTC: MNTR)

"The United States constitutes 35% of the global pharmaceutical market, the largest market in the world, and a major driver of the U.S. economy. It is one of many industries that will be impacted by the growth of the legal cannabis market and we are already starting to see that trend in legal medical states where use of key prescription drugs is down by 11%. If cannabis were to be adopted nationally, we would begin to see a trend of patients turning to medical cannabis as a substitute or complement to pharmaceuticals," said Giadha Aguirre De Carcer, CEO & Founder, New Frontier Data.

ChineseInvestors.com, Inc. (OTCQB: CIIX) announced earlier today, "It will attend the 6th Annual SeeThru Equity Microcap Investor Conference taking place today at 101 Park Avenue, New York, NY.

SeeThru Equity gave CIIX a target price of $2.05 one year ago," says Warren Wang, Founder and CEO of CIIX. He further added, "Recently, the firm increased CIIX's price target to $3.75, reflecting huge growth potential based on our legal medical cannabis initiatives. In addition, SeeThru Equity also gave CIIX a forecast for revenue from its hemp business, projecting the revenue could grow from $0.7 million in FY2017 to reach 8-digit sales by FY2020E, with continued growth thereafter.

CIIX is in the early stages of penetrating the world's legal medical cannabis market; however, increased market opportunity paired with our demonstrated insight of investing in the medical cannabis industry will enable the Company to capitalize on a unique approach to broad medical cannabis industry growth. We sincerely encourage you to come to our booth at the SeeThru Equity Microcap Investor Conference to learn more about CIIX and the incredible opportunities that wait."

Last week the company also announced, "Chinesehempoil.com Inc., established last month as a wholly owned subsidiary of CIIX, will officially launch its own premium hemp health product line 'OptHemp' which will include the Company's first private label product, OptHemp Ultra Premium Hemp Oil.

CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. On May 6th, CV Sciences announced the appointment of Stephen M. Schmitz, MD, MPH to its Board of Directors effective from May 10th, 2017. CV Sciences' President and CEO Michael J. Mona, Jr. commented, "We are very pleased to have Dr. Schmitz join our Board and look forward to his contributions. His extensive medical background and proven track record in the pharmaceutical industry, including his safety and regulatory expertise, will be invaluable to us as we move our drug development program forward to commercialization."

Cannabis Sativa, Inc. (OTCQB: CBDS) announced today that it entered into an agreement to acquire the intellectual property for the White Rabbit brand of cannabis sprays and cannabis mints, http://www.enjoywhiterabbit.com . The acquisition will include the exclusive and proprietary product formulations, product mixes, manufacturing methods and branding. The White Rabbit product line currently consists of fast acting low dose cannabis oral sprays and popular low dose cannabis mints. Both the spray and the mints are formulated as CBD only, THC only and CBD/THC blends. Dosage ranges include 2.5mg, 5mg and 10mg tablets and sprays with 1:1 and 20:1 variations of each.

Medical Marijuana, Inc. (OTC: MJNA) announced recently that new hires this month aimed at assisting the company with its further expansion into international markets, including Europe. A Company of Firsts®, Medical Marijuana, Inc. was the first to create an international CBD market when the company began retailing CBD hemp oil products sourced from hemp grown in Europe. CBD hemp oil products from Medical Marijuana, Inc. are now currently available in over 40 countries internationally. "We are extremely excited to become the first direct selling company featuring phyto-cannabinoid based products to have operations in Europe and to share our products, culture and mission throughout Europe," said Kannaway ® CEO Blake Schroeder in speaking of the opportunity for expansion in Europe. "Furthermore, Jakub is an incredible addition to our team, and we are confident that his background and passion will help ensure that Kannaway® Europe is a success."

Mentor Capital, Inc. (OTCQB: MNTR) acquires and provides liquidity for medical and social use cannabis companies. On May 03, 2017, the company announced that it has extended its funding to G FarmaLabs by an extra 20% with an additional loan on top of last month's million dollar investment in this global cannabis leader founded under the vision, energy and genius of Ata Gonzalez. Mentor Capital CEO, Chet Billingsley, concurs, "We look to work through and with G Farma to receive, channel and in some cases approve major cannabis recipients of the investor funds we send across the bridge into G Farma or to other major operators they endorse. Our particular core focus is larger cannabis companies that, like G Farma, could benefit from sophisticated mentoring toward an IPO in addition to our significant cash investment."

Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com    

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. We also do not include any personal opinions or commentary. For this release, FinancialBuzz.com expects to be compensated three thousand dollars for financial news dissemination and pr services by chineseInvestors.com inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has signed a two year agreement with chineseinvestors.com inc. for one hundred thousand restricted common shares for continued financial news dissemination and pr services. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com

For further information:
Media Contact:
info@financialbuzz.com
+1-877-601-1879

Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com